dc.contributor.author | Rodrigo, Guilermo | |
dc.contributor.author | Ruiz González, Raúl | |
dc.contributor.author | Montagud Martínez, Roser | |
dc.contributor.author | Dorta Gorrín, Alexis | |
dc.contributor.author | Pablo Marcos, Daniel | |
dc.contributor.author | Gozalo Margüello, Mónica | |
dc.contributor.author | Calvo Montes, Jorge | |
dc.contributor.author | Navas Méndez, Jesús | |
dc.contributor.other | Universidad de Cantabria | es_ES |
dc.date.accessioned | 2024-05-02T11:08:40Z | |
dc.date.available | 2024-05-02T11:08:40Z | |
dc.date.issued | 2024-04-11 | |
dc.identifier.issn | 2470-1343 | |
dc.identifier.other | PDC2022-133941-I00 | es_ES |
dc.identifier.uri | https://hdl.handle.net/10902/32719 | |
dc.description.abstract | Gene sequencing in back of reverse transcription-quantitative polymerase chain reaction (RT-qPCR) is the current approach for discriminating infections produced by different severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants in the clinic. However, sequencing is often a time-consuming step, which hinders the deployment of a very fast response during a pandemic. Here, we propose to run a CRISPR-Cas12a reaction after completing the RT-qPCR and in the very same pot to detect with high specificity genetic marks characterizing variants of concern. A crRNA was appropriately designed to detect the S gene of the SARS-CoV-2 Omicron BA.1 variant. A significant response with >20-fold dynamic range was obtained for the Omicron BA.1 S gene, while the Delta S gene did not produce any detectable signal. The sensitivity of the method was analyzed with a series of diluted samples and different Cas12a nucleases. A correlation between the RT-qPCR CT values and the CRISPR-Cas12a reaction signals was observed. Variant discrimination with the CRISPR-Cas12a reaction was possible in some minutes with high accuracy from patient samples. In conclusion, CRISPR-Cas systems seem ready to be exploited in the clinic to boost personalized diagnoses and accelerate epidemiological surveillance in a cost-effective way. | es_ES |
dc.description.sponsorship | Work supported by Generalitat Valenciana (GVA-COVID19/2021/036), Ministerio de Ciencia e Innovación (PDC2022−133941-I00; cofunded by NextGenerationEU), CRUE and Banco Santander (Fondo Supera Covid-19), CSIC PTI Salud Global (NextGenerationEU Fund, regulation 2020/2094), and IDIVAL (INNVAL21/13). | es_ES |
dc.format.extent | 5 p. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | American Chemical Society | es_ES |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.source | ACS Omega 2024, 9, 18046-18050 | es_ES |
dc.subject.other | CRISPR diagnostics | es_ES |
dc.subject.other | Infectious disease | es_ES |
dc.subject.other | Virus evolution | es_ES |
dc.title | Rapid and accurate detection of the SARS-CoV-2 omicron variant with a CRISPR-Cas12a reaction in the RT-qPCR Pot | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.rights.accessRights | openAccess | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023/PDC2022-133941-I00/ES/DESARROLLO DE UNA PLATAFORMA DE DIAGNOSTICO RAPIDO BASADA EN DESPLAZAMIENTO DE HEBRAS MEDIADO POR CRISPR-CAS9 PARA LA DETECCION MULTIPLEXADA DE ACIDOS NUCLEICOS/ | |
dc.identifier.DOI | 10.1021/acsomega.3c09717 | |
dc.type.version | publishedVersion | es_ES |